The FDA has transitioned to a "new era" of proactive enforcement, issuing warning letters to telehealth and pharmaceutical companies to eliminate misleading promotional claims and ensure a fair balance of risks and benefits regarding approved and compounded GLP-1 medications
Lotan A, Luza S, Opazo CM, Ayton S, Lane DJ, Mancuso S, et al
Sanz-Cuesta T, Gonzlez-Escobar P, Riesgo-Fuertes R, Garrido-Elustondo S, del Cura-Gonzlez I, Martn-Fernndez J, Escortell-Mayor E, Rodrguez-Salvans F, Garca-Solano M, Gonzlez-Gonzlez R, Martn-de la Sierra M
Medical Clearance and Risk Stratification Before GLP-1 Use Before starting any GLP-1 therapy after a pancreatitis episode, comprehensive medical evaluation is necessary
Why the day you choose technically does not matter Tirzepatide has a half-life of approximately five days